Edition:
United States

Seres Therapeutics Inc (MCRB.OQ)

MCRB.OQ on NASDAQ Stock Exchange Global Select Market

7.77USD
18 May 2018
Change (% chg)

$-0.58 (-6.95%)
Prev Close
$8.35
Open
$8.39
Day's High
$8.40
Day's Low
$7.76
Volume
52,926
Avg. Vol
42,070
52-wk High
$17.33
52-wk Low
$6.65

Chart for

About

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on... (more)

Overall

Beta: --
Market Cap(Mil.): $339.41
Shares Outstanding(Mil.): 40.65
Dividend: --
Yield (%): --

Financials

  MCRB.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -2.27 -- --
ROI: -53.72 -8.07 12.63
ROE: -151.17 -10.87 14.50

BRIEF-Seres Therapeutics Reports Qtrly Loss Per Share Of $0.69

* SERES THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES

May 09 2018

BRIEF-Nestle Health Science Us Holdings, Inc Reports 16.97 Pct Stake In Seres Therapeutics Inc

* Nestle Health Science Us Holdings, Inc Reports 16.97 Pct Stake In Seres Therapeutics Inc As Of April 10, 2018 - SEC Filing Source text (https://bit.ly/2GSzKlq) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 11 2018

Seres Therapeutics wins dismissal of investor lawsuit over drug study

Biopharmaceutical company Seres Therapeutics Inc has won the dismissal of a lawsuit claiming it misled investors about the potential of an oral microbiome therapeutic drug that it was developing.

Apr 02 2018

BRIEF-Seres Therapeutics Qtrly Net Loss Of $29.0 Mln Vs $25.3 Mln

* SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

Mar 08 2018

BRIEF-Seres Therapeutics Says Has Cash, Cash Equivalents And Investments Of $171.3 Mln

* SERES THERAPEUTICS SAYS HAS CASH, CASH EQUIVALENTS AND INVESTMENTS OF $171.3 MILLION, AS OF SEPT 30, 2017 - SEC FILING Source text: (http://bit.ly/2qFSBN0) Further company coverage:

Jan 08 2018

BRIEF-Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis

* SERES THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SER-287 IN TREATMENT OF PEDIATRIC ULCERATIVE COLITIS

Dec 04 2017

Earnings vs. Estimates